PASSAGE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.2 USD | -5.51% |
|
-11.76% | +18.81% |
| Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 04 | Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer | CI |
Presenter SpeechNeena Bitritto-Garg (Analysts)All right. Hi, everyone. Thank you so much for j...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimerâs disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.2
USD
Average target price
7
USD
Spread / Average Target
+483.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.81% | 78.25M | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Transcript : Passage Bio, Inc. Presents at Citi 15th Annual Biopharma Virtual Conference 2020, Sep-10-2020 03
